BIIB - Biogen

-

$undefined

N/A

(N/A)

Biogen NasdaqGS:BIIB Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Location: 225 Binney Street, Cambridge, MA, 02142, United States | Website: https://www.biogen.com | Industry: Drug Manufacturers - General | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

23.47B

Cash

2.598B

Avg Qtr Burn

N/A

Short % of Float

2.29%

Insider Ownership

0.22%

Institutional Own.

92.84%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
QALSODY™ BIIB067 (tofersen) Details
Amyotrophic lateral sclerosis

Approved

Update

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

TOFIDENCE (BIIB800) (tocilizumab) Details
Polyarticular juvenile idiopathic arthritis, Rheumatoid arthritis

Approved

Quarterly sales

PDUFA

Approval decision

Felzartamab Details
Kidney transplantation, Primary Membranous Nephropathy, IgA nephropathy, Antibody-mediated rejection

Phase 3

Update

Dapirolizumab pegol Details
Systemic lupus erythematosus

Phase 3

Initiation

Nusinersen (SPINRAZA) Details
Spinal muscular atrophy

Phase 2/3

Update

BIIB124 Details
Essential tremor

Phase 2b

Data readout

BIIB080 (tau ASO) Details
Alzheimer's disease

Phase 2

Data readout

IONS582 /BIIB121 Details
Angelman Syndrome

Phase 1b

Data readout

BIIB113 Details
Alzheimer's disease

Phase 1

Update

BIIB093 (IV glibenclamide) Details
Acute myocardial infarction

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

ATXN2 ASO (BIIB105) Details
Amyotrophic lateral sclerosis

Failed

Discontinued